Dear Editor,

We would like to thank the reviewers for their valuable comments.

We have highlighted the changes in the text.

We hope that now You will find it suitable for publication in the Journal.

Here is a point-by-point response to the reviewers' comments and concerns.

Best regards,

Reviewer#1:

It is useful manuscript. However, recalibration is desired based on the consideration including the following papers. 1.Reduced expression of thrombopoietin is involved in Thrombocytopenia in human and rat liver cirrhosis. J Gastroenterol Hepatol 1998; 13:907-913. doi: 10.1111/j.1440-1746.1998.tb00760.x. PMID: 9794189 2. Expression of hepatic thrombopoietin mRNA in primary cultured hepatocytes and in rats with acute liver injury or bone marrow suppression with or without cirrhosis. J Gastroenterol Hepatol 2000; 15: 647-653. doi: 10.1046/j.1440-1746.2000.02087.x. PMID: 10921419 3. Thrombopoietin receptor (c-Mpl) is constitutively expressed on platelets of patients with liver cirrhosis and correlates with its disease progression. Hepatol Res 2002; 23: 115-121. doi: 10.1016/s1386-6346(01)00170-x. PMID: 12048065 4. Real world data of thrombopoietin receptor for thrombocytopenia with chronic liver disease. Digestive Medicine Research 2021;4:41 https://dx.doi.org/10.21037/dmr-21-68 5. Efficacy and safety of repeated use of lusutrombopag prior to radiofrequency ablation in patients with recurrent hepatocellular carcinoma and thrombocytopenia. Hepatol Res. 2019 May;49(5):590-593. 6. Impact of Platelet Count on Perioperative Bleeding in Patients With Cirrhosis Undergoing Surgical Treatments of Liver Cancer Hepatology Communications 2021.

Authors reply: As suggested, we have now updated the manuscript in order to integrate all suggested literature.

Reviewer #2:

This review fully summarized the recent advances on the pathophysiology of thrombocytopenia in chronic liver disease and provided the new therapeutic strategies before invasive procedures. The writing quality of this review is very high, and it has a good reference value for the development of related clinical work.

Authors reply: Thanks for your comments.